Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications? [electronic resource]
Producer: 20190110Description: 479-480 p. digitalISSN:- 1433-8726
- Androgen Antagonists -- therapeutic use
- Androstenes -- administration & dosage
- Antineoplastic Agents -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Benzamides
- Clinical Trials, Phase III as Topic
- Docetaxel -- administration & dosage
- Humans
- Male
- Nitriles
- Phenylthiohydantoin -- administration & dosage
- Prostatic Neoplasms, Castration-Resistant -- drug therapy
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Letter
There are no comments on this title.
Log in to your account to post a comment.